Q2 FY2026 EarningsQ2 FY2026 missed consensus as operating loss widened to $10.63M vs. $9.08M expected, driven by a 62% YoY surge in R&D and a one-time $1.0M arbitration charge. While revenue remained at $0 as expected, Diluted EPS of -$0.05 slightly underperformed the -$0.045 consensus. The company ended the quarter with a significantly strengthened cash position of $138.3M following $82.9M in warrant exercises, providing a runway of at least 12 months despite the 3D Medicines arbitration setback.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Sellas Life Sciences(SLS) the EBIT is -10.63 M (-54.65%), Miss estimate;the EPS is -0.05 (+28.57%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.01B54.65%
-0.01B32.11%
-0.00B22.54%
EPSMiss expectations
-0.0528.57%
-0.04535.71%
-0.00507.14%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf